|
1
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Certo M, Del Gaizo Moore V, Nishino M, et
al: Mitochondria primed by death signals determine cellular
addiction to anti-apoptotic BCL-2 family members. Cancer Cell.
9:351–365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim H, Rafiuddin-Shah M, Tu HC, et al:
Hierarchical regulation of mitochondrion-dependent apoptosis by
BCL-2 subfamilies. Nat Cell Biol. 8:1348–1358. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oltersdorf T, Elmore SW, Shoemaker AR, et
al: An inhibitor of Bcl-2 family proteins induces regression of
solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Gaizo Moore V, Brown JR, Certo M, Love
TM, Novina CD and Letai A: Chronic lymphocytic leukemia requires
BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2
antagonist ABT-737. J Clin Invest. 117:112–121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chauhan D, Velankar M, Brahmandam M, et
al: A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in
multiple myeloma. Oncogene. 26:2374–2380. 2007. View Article : Google Scholar
|
|
7
|
Konopleva M, Contractor R, Tsao T, et al:
Mechanisms of apoptosis sensitivity and resistance to the BH3
mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Delft MF, Wei AH, Mason KD, et al: The
BH3 mimetic ABT-737 targets selective Bcl-2 proteins and
efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Cancer Cell. 10:389–399. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andrews PD, Knatko E, Moore WJ and Swedlow
JR: Mitotic mechanics: the auroras come into view. Curr Opin Cell
Biol. 15:672–683. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirota T, Kunitoku N, Sasayama T, et al:
Aurora-A and an interacting activator, the LIM protein Ajuba, are
required for mitotic commitment in human cells. Cell. 114:585–598.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Farag SS: The potential role of Aurora
kinase inhibitors in haematological malignancies. Br J Haematol.
155:561–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gautschi O, Heighway J, Mack PC, Purnell
PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug
targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gritsko TM, Coppola D, Paciga JE, et al:
Activation and overexpression of centrosome kinase BTAK/Aurora-A in
human ovarian cancer. Clin Cancer Res. 9:1420–1426. 2003.PubMed/NCBI
|
|
14
|
Katayama H, Brinkley WR and Sen S: The
Aurora kinases: role in cell transformation and tumorigenesis.
Cancer Metastasis Rev. 22:451–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tallarida RJ: Drug synergism: its
detection and applications. J Pharmacol Exp Ther. 298:865–872.
2001.PubMed/NCBI
|
|
16
|
Mitchell T and Sugden B: Stimulation of
NF-kappa B-mediated transcription by mutant derivatives of the
latent membrane protein of Epstein-Barr virus. J Virol.
69:2968–2976. 1995.PubMed/NCBI
|
|
17
|
Harrington EA, Bebbington D, Moore J, et
al: VX-680, a potent and selective small-molecule inhibitor of the
Aurora kinases, suppresses tumor growth in vivo. Nat Med.
10:262–267. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pugazhenthi S, Miller E, Sable C, et al:
Insulin-like growth factor-I induces bcl-2 promoter through the
transcription factor cAMP-response element-binding protein. J Biol
Chem. 274:27529–27535. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamatani M, Che YH, Matsuzaki H, et al:
Tumor necrosis factor induces Bcl-2 and Bcl-x expression through
NFkappaB activation in primary hippocampal neurons. J Biol Chem.
274:8531–8538. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Catz SD and Johnson JL: Transcriptional
regulation of bcl-2 by nuclear factor kappa B and its significance
in prostate cancer. Oncogene. 20:7342–7351. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bourgarel-Rey V, Savry A, Hua G, et al:
Transcriptional down-regulation of Bcl-2 by vinorelbine:
identification of a novel binding site of p53 on Bcl-2 promoter.
Biochem Pharmacol. 78:1148–1156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haldar S, Negrini M, Monne M, Sabbioni S
and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer
cells. Cancer Res. 54:2095–2097. 1994.PubMed/NCBI
|
|
23
|
Wu Y, Mehew JW, Heckman CA, Arcinas M and
Boxer LM: Negative regulation of bcl-2 expression by p53 in
hematopoietic cells. Oncogene. 20:240–251. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ciechanover A and Schwartz AL: The
ubiquitin system: pathogenesis of human diseases and drug
targeting. Biochim Biophys Acta. 1695:3–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song JH, Kandasamy K and Kraft AS: ABT-737
induces expression of the death receptor 5 and sensitizes human
cancer cells to TRAIL-induced apoptosis. J Biol Chem.
283:25003–25013. 2008. View Article : Google Scholar : PubMed/NCBI
|
